Verena Kast, Ali Nadernezhad, Dagmar Pette, Anastasiia Gabrielyan, Maximilian Fusenig, Kim C. Honselmann, Daniel E. Stange, Carsten Werner, Daniela Loessner
doi : 10.1002/adhm.202370070
Gevick Safarians, Alireza Sohrabi, Itay Solomon, Weikun Xiao, Soniya Bastola, Bushra W. Rajput, Mary Epperson, Isabella Rosenzweig, Kelly Tamura, Breahna Singer, Joyce Huang, Mollie J. Harrison, Talia Sanazzaro, Michael C. Condro, Harley I. Kornblum, Stephanie K. Seidlits
doi : 10.1002/adhm.202370071
Carlos F. Guimarães, Daniela Cruz-Moreira, David Caballero, Rogério P. Pirraco, Luca Gasperini, Subhas C. Kundu, Rui L. Reis
doi : 10.1002/adhm.202370073
Kenny Zhuoran Wu, Christabella Adine, Aleksandr Mitriashkin, Benjamin Jun Jie Aw, N. Gopalakrishna Iyer, Eliza Li Shan Fong
doi : 10.1002/adhm.202370074
Kristopher Kilian, Claudia Fischbach, Eliza Li Shan Fong
doi : 10.1002/adhm.202300411
Carlos F. Guimarães, Daniela Cruz-Moreira, David Caballero, Rogério P. Pirraco, Luca Gasperini, Subhas C. Kundu, Rui L. Reis
doi : 10.1002/adhm.202201442
Kenny Zhuoran Wu, Christabella Adine, Aleksandr Mitriashkin, Benjamin Jun Jie Aw, N. Gopalakrishna Iyer, Eliza Li Shan Fong
doi : 10.1002/adhm.202202279
As a reductionist approach, patient-derived in vitro tumor models are inherently still too simplistic for personalized drug testing as they do not capture many characteristics of the tumor microenvironment (TME), such as tumor architecture and stromal heterogeneity.
Ren Yuan Lee, Yang Wu, Denise Goh, Verlyn Tan, Chan Way Ng, Jeffrey Chun Tatt Lim, Mai Chan Lau, Joe Poh Sheng Yeong
doi : 10.1002/adhm.202202457
In vitro tumor models have played vital roles in enhancing the understanding of the cellular and molecular composition of tumors, as well as their biochemical and biophysical characteristics.
Jana Sievers, Vaibhav Mahajan, Petra B. Welzel, Carsten Werner, Anna Taubenberger
doi : 10.1002/adhm.202202514
Cancer progression is associated with extensive remodeling of the tumor microenvironment (TME), resulting in alterations of biochemical and biophysical cues that affect both cancer and stromal cells. In particular, the mechanical characteristics of the TME extracellular matrix undergo significant changes.
Verena Kast, Ali Nadernezhad, Dagmar Pette, Anastasiia Gabrielyan, Maximilian Fusenig, Kim C. Honselmann, Daniel E. Stange, Carsten Werner, Daniela Loessner
doi : 10.1002/adhm.202201907
Pancreatic cancer is a devastating malignancy with minimal treatment options. Standard-of-care therapy, including surgery and chemotherapy, is unsatisfactory, and therapies harnessing the immune system have been unsuccessful in clinical trials.
Gevick Safarians, Alireza Sohrabi, Itay Solomon, Weikun Xiao, Soniya Bastola, Bushra W. Rajput, Mary Epperson, Isabella Rosenzweig, Kelly Tamura, Breahna Singer, Joyce Huang, Mollie J. Harrison, Talia Sanazzaro, Michael C. Condro, Harley I. Kornblum, Stephanie K. Seidlits
doi : 10.1002/adhm.202203143
Increased secretion of hyaluronic acid (HA), a glycosaminoglycan abundant in the brain extracellular matrix (ECM), correlates with worse clinical outcomes for glioblastoma (GBM) patients. GBM cells aggressively invade the brain parenchyma while encountering spatiotemporal changes in their local ECM, including HA concentration.
Lindsey K. Sablatura, Kristin M. Bircsak, Peter Shepherd, Madhavi Bathina, Karla Queiroz, Mary C. Farach-Carson, Rick A. Kittles, Pamela E. Constantinou, Anthony Saleh, Nora M. Navone, Daniel A. Harrington
doi : 10.1002/adhm.202201434
Many advanced cancer models, such as patient-derived xenografts (PDXs), offer significant benefits in their preservation of the native tumor's heterogeneity and susceptibility to treatments, but face significant barriers to use in their reliance on a rodent host for propagation and screening.
Naveen Vijayan Mekhileri, Gretel Major, Khoon Lim, Isha Mutreja, Kenny Chitcholtan, Elisabeth Phillips, Gary Hooper, Tim Woodfield
doi : 10.1002/adhm.202201581
To streamline the drug discovery pipeline, there is a pressing need for preclinical models which replicate the complexity and scale of native tumors. While there have been advancements in the formation of microscale tumor units, these models are cell-line dependent, time-consuming and have not improved clinical trial success rates.
Yiling Liu, Stephanie Nemec, Chantal Kopecky, Martina H. Stenzel, Kristopher A. Kilian
doi : 10.1002/adhm.202201696
Nanoparticle drug formulations have many advantages for cancer therapy due to benefits in targeting selectivity, lack of systemic toxicity, and increased drug concentration in the tumor microenvironment after delivery.
Agathe Bessot, Jennifer Gunter, David Waugh, Judith A. Clements, Dietmar W. Hutmacher, Jacqui McGovern, Nathalie Bock
doi : 10.1002/adhm.202201701
reasing evidence shows bone marrow (BM)-adipocytes as a potentially important contributor in prostate cancer (PCa) bone metastases. However, a lack of relevant models has prevented the full understanding of the effects of human BM-adipocytes in this microenvironment.
Auxtine Micalet, Judith Pape, Deniz Bakkalci, Yousef Javanmardi, Chloe Hall, Umber Cheema, Emad Moeendarbary
doi : 10.1002/adhm.202201749
The stiffness of tumors and their host tissues is much higher than most hydrogels, which are conventionally used to study in vitro cancer progression. The tumoroid assay is an engineered 3D in vitro tumor model that allows investigation of cancer cell invasion in an environment that is biomimetic in terms of extracellular matrix (ECM) composition and stiffness.
Zhengpeng Wan, Marie A. Floryan, Mark F. Coughlin, Shun Zhang, Amy X. Zhong, Sarah E. Shelton, Xun Wang, Chenguang Xu, David A. Barbie, Roger D. Kamm
doi : 10.1002/adhm.202201784
Previous studies have developed vascularized tumor spheroid models to demonstrate the impact of intravascular flow on tumor progression and treatment. However, these models have not been widely adopted so the vascularization of tumor spheroids in vitro is generally lower than vascularized tumor tissues in vivo.
Aereas Aung, Shruti K. Davey, Jomkuan Theprungsirikul, Vardhman Kumar, Shyni Varghese
doi : 10.1002/adhm.202201842
Uncontrolled growth of tumor cells is a key contributor to cancer-associated mortalities. Tumor growth is a biomechanical process whereby the cancer cells displace the surrounding matrix that provides mechanical resistance to the growing cells.
Jose L. Cadavid, Simon Latour, Ferris Nowlan, Ileana L. Co, Natalie Landon-Brace, Bradly G. Wouters, Barbara T. Grünwald, Mark Nitz, Hartland Warren Jackson, Alison P. McGuigan
doi : 10.1002/adhm.202201846
The spatial configuration of cells in the tumor microenvironment (TME) affects both cancer and fibroblast cell phenotypes contributing to the clinical challenge of tumor heterogeneity and therapeutic resistance. This is a particular challenge in stroma-rich pancreatic ductal adenocarcinoma (PDAC).
Maria K. Koch, Akhilandeshwari Ravichandran, Berline Murekatete, Julien Clegg, Mary Teresa Joseph, Madison Hampson, Mitchell Jenkinson, Hannah S. Bauer, Cameron Snell, Cheng Liu, Madeline Gough, Erik W. Thompson, Carsten Werner, Dietmar W. Hutmacher, Larisa M. Haupt, Laura J. Bray
doi : 10.1002/adhm.202202202
Breast cancer is a complex, highly heterogenous, and dynamic disease and the leading cause of cancer-related death in women worldwide. Evaluation of the heterogeneity of breast cancer and its various subtypes is crucial to identify novel treatment strategies that can overcome the limitations of currently available options.
Adrian A. Shimpi, Matthew L. Tan, Michael Vilkhovoy, David Dai, LaDeidra Monet Roberts, Joe Chin-Hun Kuo, Lingting Huang, Jeffrey D. Varner, Matthew Paszek, Claudia Fischbach
doi : 10.1002/adhm.202202224
Metastasis is the leading cause of breast cancer-related deaths and is often driven by invasion and cancer-stem like cells (CSCs). Both the CSC phenotype and invasion are associated with increased hyaluronic acid (HA) production.
Hyuna Kim, Anna Wirasaputra, Farnaz Mohammadi, Aritra Nath Kundu, Jennifer A. E. Esteves, Laura M. Heiser, Aaron S. Meyer, Shelly R. Peyton
doi : 10.1002/adhm.202202275
Breast cancer is a leading cause of global cancer-related deaths, and metastasis is the overwhelming culprit of poor patient prognosis. The most nefarious aspect of metastasis is dormancy, a prolonged period between primary tumor resection and relapse. Current therapies are insufficient at killing dormant cells; thus, they can remain quiescent in the body for decades until eventually undergoing a phenotypic switch, resulting in metastases that are more adaptable and drug resistant.
Zerin Mahzabin Khan, Jennifer M. Munson, Timothy E. Long, Eli Vlaisavljevich, Scott S. Verbridge
doi : 10.1002/adhm.202300671
Glioblastoma (GBM), characterized by high infiltrative capacity, is the most common and deadly type of primary brain tumor in adults. GBM cells, including therapy-resistant glioblastoma stem-like cells (GSCs), invade the healthy brain parenchyma to form secondary tumors even after patients undergo surgical resection and chemoradiotherapy.
Do you want to add Medilib to your home screen?